Belite Bio (BLTE) is positioned for upside with tinlarebant, an oral therapy for Stargardt disease, following a successful Phase 3 DRAGON trial and NDA submission. BLTE's oral systemic approach offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results